Bioequivalence Program - Successful Completion of Phase 1 by Kwality Pharmaceuticals Ltd

Kwality Pharmaceuticals Ltd. (KPL) had initiated an extensive Bioequivalence (BE) program covering more than 30 molecules across key therapeutic segments, including Oncology, Cardiology Anti-diabetics, and Anti-hypertensives. The portfolio comprises a balanced mix of both patented and off-patent complex molecules. To execute this initiative, KPL has partnered with four globally accredited Contract Research Organizations (CROs).

The program has been structured in a phased manner to ensure efficient execution and regulatory alignment. We are pleased to announce the successful completion of Phase 1, with BE studies for Hydroxycarbamide, Nilotinib, and Liposomal Amphotericin B completed successfully.

These dossiers are now prepared for submission across regulated, semi-regulated, and Rest of the World (ROW) markets, further strengthening KPL's global regulatory footprint and commitment to expanding access to high-quality pharmaceutical products.

Shares of Kwality Pharmaceuticals Ltd was last trading in BSE at Rs. 1662.90 as compared to the previous close of Rs. 1559.70. The total number of shares traded during the day was 50610 in over 3149 trades.

The stock hit an intraday high of Rs. 1710.00 and intraday low of 1576.45. The net turnover during the day was Rs. 83237414.00.

Source : Equity Bulls

Keywords

KwalityPharmaceuticals INE552U01010 BioequivalenceProgram